Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PATHO-LEGO

Financiado

All-in-one supramolecular approach as an innovative anti-infectious strategy

"Despite the large therapeutic arsenal available to fight bacterial infections, the development of new anti-infectious strategies is a major public health concern. Pathogens have indeed developed a variety of Multi Drug Resistance... ver más

30/06/2024

UGA

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UGA

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STICKY SUGARS Sweet adhesins: Probing bacterial glycoproteins with novel t... 1M€ Cerrado

PDC2021-121544-I00 DISEÑO DE UNA NUEVA CLASE DE ANTIMICROBIANOS CONTRA INFECCIO... 133K€ Cerrado

vAMRes Vaccines as a remedy for antimicrobial resistant bacterial i... 2M€ Cerrado

PID2020-113588RB-I00 APROXIMACIONES DE LA QUIMICA COMPUTACIONAL A MECANISMOS DE L... 145K€ Cerrado

NovAnI Indentification and optimisation of novel anti infective age... 1M€ Cerrado

resistance evolution Bacterial evolution of hypersensitivity and resistance again... 2M€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2022-11-17
Fecha Fin: 2024-06-30

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto "Despite the large therapeutic arsenal available to fight bacterial infections, the development of new anti-infectious strategies is a major public health concern. Pathogens have indeed developed a variety of Multi Drug Resistance mechanisms to escape destruction. To circuvment these problems, a few promising alternatives have been proposed. A first one focuses on the bacterial adhesion step to the host cells which involves multivalent interactions between the glycocalix and bacterial adhesins. Molecular constructs displaying clusters of carbohydrates have been shown to efficiently compete with these complex recognition processes, thus having the potential to prevent this key step of the bacterial infection. The recruitment of natural antibodies (NAbs) present in the human bloodsteam against biological targets to stimulate their destruction by the immune system is another alternative to fight pathogens. This approach is based on the utilization of bimodal molecules (namely ARGs, Antibody Recruiting Glycodendrimers) which are composed of two recognition domains, one for NAbs and one for receptors expressed by the pathogen. The potential of this ""recruiting strategy"" was demonstrated recently in the PI's team in the context of cancers where NAbs have been efficiently redirected against tumors (ERC CoG LEGO and ERC PoC THERA-LEGO). For the first time, PATHO-LEGO will take advantage of these two ""antiadhesive"" and ""recruitment"" strategies simultaneously to fight resistant strains of Pseudomonas aeruginosa. We aim at developing hybrid ARGs that will block extracellular process that P. aeruginosa uses to infect host cells on the one hand, and that will redirect NAbs against the bacteria to induce their immune-mediated clearance on the other hand. With this unprecedented approach, we will be able to both prevent infection and kill the targeted resistant bacteria to optimize the antibacterial effect."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores